Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

CD19 Universal CAR-T cells

Three dose groups (1×10\^7/kg, 3×10\^7/kg, 6×10\^7/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.

Trial Locations (1)

310052

RECRUITING

Children's Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

The Children's Hospital of Zhejiang University School of Medicine

OTHER